Heterozygous inactivation of the NF1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway

Human Molecular Genetics

Volumn 22, Issue 5, 2013, Pages 977-988

  Stansfield, Brian K ^a   Bessler, Waylan K ^a   Mali, Raghuveer ^a   Mund, Julie A ^a   Downing, Brandon ^a   Li, Fang ^a   Sarchet, Kara N ^a   DiStasi, Matthew R ^a   Conway, Simon J ^a   Kapur, Reuben ^a   Ingram, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN; ROSUVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CAROTID ARTERY INJURY; CAROTID ARTERY OBSTRUCTION; CELL ADHESION; CELL LINEAGE; CELL MOTILITY; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; EFFECTOR CELL; GENE DOSAGE; GENE INACTIVATION; HETEROZYGOSITY; IN VIVO STUDY; MACROPHAGE; MACROPHAGE MIGRATION; MALE; MONOCYTE; MOUSE; NEOINTIMA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIAL OCCLUSIVE DISEASES; BONE MARROW CELLS; FLUOROBENZENES; HETEROZYGOTE; HUMANS; MACROPHAGES; METABOLIC NETWORKS AND PATHWAYS; MICE; MYELOID CELLS; NEOINTIMA; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PYRIMIDINES; SULFONAMIDES;

EID: 84873416941     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds502     Document Type: Article

References (54)

1. Riccardi, V.M. (1991) Neurofibromatosis: past, present, and future. N. Engl. J. Med., 324, 1283-1285.
2. Clark, G.J., Drugan, J.K., Terrell, R.S., Bradham, C., Der, C.J., Bell, R.M. and Campbell, S. (1996) Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. Proc. Natl. Acad. Sci. USA, 93, 1577-1581.
3. Viskochil, D., Buchberg, A.M., Xu, G., Cawthon, R.M., Stevens, J., Wolff, R.K., Culver, M., Carey, J.C., Copeland, N.G., Jenkins, N.A. et al. (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell, 62, 187-192.
4. Friedman, J.M., Arbiser, J., Epstein, J.A., Gutmann, D.H., Huot, S.J., Lin, A.E., McManus, B. and Korf, B.R. (2002) Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet. Med., 4, 105-111.
5. Rasmussen, S.A., Yang, Q. and Friedman, J.M. (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am. J. Hum. Genet., 68, 1110-1118.
6. Fossali, E., Signorini, E., Intermite, R.C., Casalini, E., Lovaria, A., Maninetti, M.M. and Rossi, L.N. (2000) Renovascular disease and hypertension in children with neurofibromatosis. Pediatr. Nephrol., 14, 806-810.
7. Lama, G., Graziano, L., Calabrese, E., Grassia, C., Rambaldi, P.F., Cioce, F., Tedesco, M.A., Di Salvo, G. and Esposito-Salsano, M. (2004) Blood pressure and cardiovascular involvement in children with neurofibromatosis type1. Pediatr. Nephrol., 19, 413-418.
8. Lin, A.E., Birch, P.H., Korf, B.R., Tenconi, R., Niimura, M., Poyhonen, M., Armfield Uhas, K., Sigorini, M., Virdis, R., Romano, C. et al. (2000) Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am. J. Med. Genet., 95, 108-117.
9. Rea, D., Brandsema, J.F., Armstrong, D., Parkin, P.C., deVeber, G., MacGregor, D., Logan, W.J. and Askalan, R. (2009) Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics, 124, e476-e483.
10. Ingram, D.A., Hiatt, K., King, A.J., Fisher, L., Shivakumar, R., Derstine, C., Wenning, M.J., Diaz, B., Travers, J.B., Hood, A. et al. (2001) Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J. Exp. Med., 194, 57-69.
11. Ingram, D.A., Yang, F.C., Travers, J.B., Wenning, M.J., Hiatt, K., New, S., Hood, A., Shannon, K., Williams, D.A. and Clapp, D.W. (2000) Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J. Exp. Med., 191, 181-188.
12. Li, F., Munchhof, A.M., White, H.A., Mead, L.E., Krier, T.R., Fenoglio, A., Chen, S., Wu, X., Cai, S., Yang, F.C. et al. (2006) Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum. Mol. Genet., 15, 1921-1930.
13. Munchhof, A.M., Li, F., White, H.A., Mead, L.E., Krier, T.R., Fenoglio, A., Li, X., Yuan, J., Yang, F.C. and Ingram, D.A. (2006) Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Hum. Mol. Genet., 15, 1858-1869.
14. Lasater, E.A., Bessler, W.K., Mead, L.E., Horn, W.E., Clapp, D.W., Conway, S.J., Ingram, D.A. and Li, F. (2008) Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. Hum. Mol. Genet., 17, 2336-2344.
15. Lasater, E.A., Li, F., Bessler, W.K., Estes, M.L., Vemula, S., Hingtgen, C.M., Dinauer, M.C., Kapur, R., Conway, S.J. and Ingram, D.A. Jr. (2010) Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J. Clin. Invest., 120, 859-870.
16. Yang, F.C., Chen, S., Robling, A.G., Yu, X., Nebesio, T.D., Yan, J., Morgan, T., Li, X., Yuan, J., Hock, J. et al. (2006) Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J. Clin. Invest., 116, 2880-2891.
17. Kiyan, J., Kusch, A., Tkachuk, S., Kramer, J., Haller, H., Dietz, R., Smith, G. and Dumler, I. (2007) Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor. Atherosclerosis, 195, 254-261.
18. Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M. Jr., Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., MacFadyen, J.G. et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 359, 2195-2207.
19. Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M. Jr., Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., Macfadyen, J.G. et al. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 373, 1175-1182.
20. Hansson, G.K. (2005) Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 352, 1685-1695.
21. Schlitt, A., Heine, G.H., Blankenberg, S., Espinola-Klein, C., Dopheide, J.F., Bickel, C., Lackner, K.J., Iz, M., Meyer, J., Darius, H. et al. (2004) CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb. Haemost., 92, 419-424.
22. Grage-Griebenow, E., Flad, H.D. and Ernst, M. (2001) Heterogeneity of human peripheral blood monocyte subsets. J. Leukoc. Biol., 69, 11-20.
23. Swirski, F.K., Libby, P., Aikawa, E., Alcaide, P., Luscinskas, F.W., Weissleder, R. and Pittet, M.J. (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest., 117, 195-205.
24. Getts, D.R., Terry, R.L., Getts, M.T., Muller, M., Rana, S., Shrestha, B., Radford, J., Van Rooijen, N., Campbell, I.L. and King, N.J. (2008) Ly6c+ inflammatory monocytes are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J. Exp. Med., 205, 2319-2337.
25. Kumar, A. and Lindner, V. (1997) Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler. Thromb. Vasc. Biol., 17, 2238-2244.
26. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R. and Forster, I. (1999) Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res., 8, 265-277.
27. Shiba, Y., Takahashi, M., Yoshioka, T., Yajima, N., Morimoto, H., Izawa, A., Ise, H., Hatake, K., Motoyoshi, K. and Ikeda, U. (2007) M-CSF accelerates neointimal formation in the early phase after vascular injury in mice: the critical role of the SDF-1-CXCR4 system. Arterioscler. Thromb. Vasc. Biol., 27, 283-289.
28. Furman, C., Copin, C., Kandoussi, M., Davidson, R., Moreau, M., McTaggiart, F., Chapman, M.J., Fruchart, J.C. and Rouis, M. (2004) Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis, 174, 93-98.
29. Li, W., Asagami, T., Matsushita, H., Lee, K.H. and Tsao, P.S. (2005) Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. J. Pharmacol. Exp. Ther., 313, 557-562.
30. Preusch, M.R., Vanakaris, A., Bea, F., Ieronimakis, N., Shimizu, T., Konstandin, M., Morris-Rosenfeld, S., Albrecht, C., Kranzhofer, A., Katus, H.A. et al. (2010) Rosuvastatin reduces neointima formation in a rat model of balloon injury. Eur. J. Med. Res., 15, 461-467.
31. Lambert, C.M., Roy, M., Meloche, J., Robitaille, G.A., Agharazii, M., Richard, D.E. and Bonnet, S. (2010) Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases. Am. J. Physiol. Heart Circ. Physiol., 299, H995-H1001.
32. Rectenwald, J.E., Moldawer, L.L., Huber, T.S., Seeger, J.M. and Ozaki, C.K. (2000) Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation, 102, 1697-1702.
33. Goetze, S., Kintscher, U., Kaneshiro, K., Meehan, W.P., Collins, A., Fleck, E., Hsueh, W.A. and Law, R.E. (2001) TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis, 159, 93-101.
34. Davignon, J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation, 109, III39-III43.
35. Schonbeck, U. and Libby, P. (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation, 109, II18-II26.
36. Chen, Z., Fukutomi, T., Zago, A.C., Ehlers, R., Detmers, P.A., Wright, S.D., Rogers, C. and Simon, D.I. (2002) Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation, 106, 20-23.
37. Jaschke, B., Michaelis, C., Milz, S., Vogeser, M., Mund, T., Hengst, L., Kastrati, A., Schomig, A. and Wessely, R. (2005) Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc. Res., 68, 483-492.
38. Largaespada, D.A., Brannan, C.I., Jenkins, N.A. and Copeland, N.G. (1996) Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat. Genet., 12, 137-143.
39. Yang, F.C., Ingram, D.A., Chen, S., Zhu, Y., Yuan, J., Li, X., Yang, X., Knowles, S., Horn, W., Li, Y. et al. (2008) Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell, 135, 437-448.
40. Rivollier, A., He, J., Kole, A., Valatas, V. and Kelsall, B.L. (2012) Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J. Exp. Med., 209, 139-155.
41. Tsou, C.L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A.M., Weisberg, S.P., Mack, M. and Charo, I.F. (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest., 117, 902-909.
42. Dong, L.H., Wen, J.K., Liu, G., McNutt, M.A., Miao, S.B., Gao, R., Zheng, B., Zhang, H. and Han, M. (2010) Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia. Arterioscler. Thromb. Vasc. Biol., 30, 683-691.
43. Jin, G., Chieh-Hsi Wu, J., Li, Y.S., Hu, Y.L., Shyy, J.Y. and Chien, S. (2000) Effects of active and negative mutants of Ras on rat arterial neointima formation. J. Surg. Res., 94, 124-132.
44. Wang, W., Nyman, J.S., Moss, H.E., Gutierrez, G., Mundy, G.R., Yang, X. and Elefteriou, F. (2010) Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J. Bone Miner. Res., 25, 1658-1667.
45. Krab, L.C., de Goede-Bolder, A., Aarsen, F.K., Pluijm, S.M., Bouman, M.J., van der Geest, J.N., Lequin, M., Catsman, C.E., Arts, W.F., Kushner, S.A. et al. (2008) Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA, 300, 287-294.
46. Halcox, J.P. and Deanfield, J.E. (2004) Beyond the laboratory: clinical implications for statin pleiotropy. Circulation, 109, II42-II48.
47. Shao, Q., Shen, L.H., Hu, L.H., Pu, J., Jing, Q. and He, B. (2012) Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IkappaBalpha degradation, and COX-2 expression in murine macrophages. J. Cell Biochem., 113, 611-618.
48. Feig, J.E., Shang, Y., Rotllan, N., Vengrenyuk, Y., Wu, C., Shamir, R., Torra, I.P., Fernandez-Hernando, C., Fisher, E.A. and Garabedian, M.J. (2011) Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One, 6, e28534.
49. Werner, N., Priller, J., Laufs, U., Endres, M., Bohm, M., Dirnagl, U. and Nickenig, G. (2002) Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol., 22, 1567-1572.
50. Yi, I., Lee, J.J., Park, J.S., Zhang, W.Y., Kim, I.S., Kim, Y., Shin, C.Y., Kim, H.S. and Myung, C.S. (2010) Enhanced effect of losartan and rosuvastatin on neointima hyperplasia. Arch. Pharm. Res., 33, 593-600.
51. Pei, Y., Ma, P., Wang, X., Zhang, W., Zhang, X., Zheng, P., Yan, L., Xu, Q. and Dai, G. (2011) Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur. J. Pharmacol., 666, 165-172.
52. Xu, H., Yang, Y.J., Qian, H.Y., Tang, Y.D., Wang, H. and Zhang, Q. (2011) Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circ. J., 75, 1476-1485.
53. Zhu, Y., Romero, M.I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E.J., Marth, J.D. and Parada, L.F. (2001) Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes. Dev., 15, 859-876.
54. Ye, M., Iwasaki, H., Laiosa, C.V., Stadtfeld, M., Xie, H., Heck, S., Clausen, B., Akashi, K. and Graf, T. (2003) Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential. Immunity, 19, 689-699.